ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, a full service Contract Research Organization, known for On-Time, On-Budget, On-Promise Clinical Trial Delivery, invites biotechnology companies and CROs to join forces in bringing novel treatments to patients sooner.
PSI will be attending the upcoming 57th ASH (American Society of Hematology) Annual Meeting in Orlando. Biotechnology sponsors are invited to join the #StopTrialDelays discussion at booth 1663 beginning Saturday, December 5th through Monday, December 7th. PSI extends the invitation to all biotech companies who are planning clinical trials in the area of hematology and oncohematology and for whom predictability and quality of clinical trial timelines are of paramount value.
PSI has generated data for break-through products in Multiple Myeloma, CML, CLL and NHL achieving unprecedented adherence to planned program timelines. Their commitment to on-time delivery of every clinical trial on the critical path allows patients to have access to many novel treatments earlier.
PSI’s commitment to timely delivery spread across most difficult-to-enroll patient populations, encompassing blood dyscrasias from the more mundane to the rarest forms of hemophilia, across different age groups throughout North and South America, South Africa, Europe and Asia.
Several biotechnology companies will join discussions at PSI’s booth 1663 and share their lessons on how to #StopTrialDelays.
“I cannot say enough great things about PSI. You made us always feel like a priority. And your entire team always worked their very best to make sure that our studies were never ignored. Your leaderships over the years will be forever in my memory. The minute I get to build the next dream team, you will be the first phone call I make!” California, USA, November 2015.
About PSI CRO AG: PSI is a privately-owned, full-service contract research organization (CRO), operating globally. PSI’s reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com
